What You Get in a NELL DeepValidate Report?

A full walkthrough of a real report, section by section, with a read on how to use each part to decide whether to build, kill, or reshape your idea.

What You Get in a NELL DeepValidate Report?

A full walkthrough of a real report, section by section, with a read on how to use each part to decide whether to build, kill, or reshape your idea.

IN SHORT

What it is: A research report that pressure-tests one startup idea and tells you whether it is worth building.

What's inside: Sourced evidence on the problem, market, competition, pricing, unit economics, and risks, plus a ready-to-use go-to-market kit.

Price: $49 per report.

Best for: Early-stage and aspiring founders deciding whether an idea deserves the next year of their life.

The bet in one line: if an idea cannot survive an evidence-based gut check for $49, far better to learn that now than after a year of building.

Why validating an idea is so hard right now?

Every founder asking “is this idea any good?” is really asking a harder question: should I spend the next year of my life building it? Most of the ways people answer that are close to useless. You ask friends, and they are nice to you. You ask a chatbot, and it is nice to everyone. You post the idea online and read the likes as proof. None of that tells you whether real buyers will actually pay.

The reason validation is hard is that doing it properly is slow and unglamorous. It means digging through forums and industry data for evidence the pain is real, sizing a market from the bottom up, mapping competitors and finding their weak spots, sanity-checking whether the unit economics can ever work, and being honest with yourself when the answer is no. Most founders skip it, not because they are lazy, but because it takes a week they would rather spend building.

A DeepValidate report does that week of work for you and puts the result on your desk, with every claim tied to a source and labelled by how confident it is. It will not build the company for you, and it is not a crystal ball. What it does is give you a clear, honest starting position so you are not betting a year on a hunch. Below is exactly what that looks like, walked through a real report end to end.

What you get, at a glance

A DeepValidate report is a multi-section research document focused on one specific idea. Here is the full contents, and we will walk through every part of it below:

Overall score and verdict: the one-screen read on whether to build.

Problem Validation: sourced evidence the pain is real and expensive.

Demand Signals: where real pull is showing up, or is not.

Market Sizing: TAM, SAM, and a bottom-up SOM you can check.

Revenue Ceiling: a realistic 24-month revenue cap, with the math shown.

Funding and Traction: whether investors are already moving on this space.

Competitive Landscape: a teardown of who is here and where they are weak.

White Space and Positioning: the lane to own, with a positioning line you can lift.

Failure Post-Mortems: what similar ideas died of.

Pricing and Willingness to Pay: what to charge, anchored to the buyer’s alternative.

Unit Economics: LTV, CAC, payback, margin, and the assumption that breaks the model.

Revenue Model: the pricing shape that actually fits the business.

Idea-Level Risks: ranked, each with a mitigation and an early-warning sign.

Recommended Next Steps: the cheapest experiments to run next, in order.

Truth Standards and Sources: every source, confidence levels, and what it could not verify.

A Go-To-Market kit: copy-paste community templates and a 90-day plan.

To make this concrete, we ran a real one.

The idea: INDbench, a fractional marketplace matching pre-seed biotech founders with retired FDA reviewers for a few hours a week during the messy IND-preparation phase. Niche, specific, the kind of thing a founder would obsess over. It scored 62 out of 100 (“Promising with Caveats”).

One thing worth knowing first: the report is not a single page, it is a full workspace. The DeepValidate tab, the deep research layer we are walking through, sits alongside tabs that carry you from validation into building.

The one-screen verdict

Open the report and the whole argument is compressed into the first screen: a headline score out of 100, a one-line verdict, a two-sentence thesis, and a bar for every dimension that feeds the number. Before you read a word of detail, you can see the shape of the entire idea.

THE OPERATOR'S READ

Don't fixate on the 62. The band matters more than the digit. “Promising with Caveats” is the middle verdict, above “Needs Refinement” and “High Risk,” below a clean green light. It means the bones are good but something specific is unresolved, and the report is about to tell you exactly what.

The bars underneath are where the real information lives. Scan for green versus amber. Here, problem and pricing are strong, while market, competition, and demand sit in the amber zone. That pattern, real pain and real willingness to pay but a crowded and unproven market, is the whole story of this idea in about five seconds.

My habit: skip the high scores and go straight to the lowest bars. Those are the things that can kill you. The question is never “is my average good,” it is “is my weakest dimension fixable before I commit money.”

The signal snapshot

Next, the report distills everything into five core signals and plots them on a single map. This is the ten-second version of the analysis, the thing you would glance at to decide whether to keep reading.

THE OPERATOR’S READ

Two of the five come back green (problem severity and willingness to pay), three amber. That mix is honest and useful. It says the pain is real and people already pay for adjacent help, but demand, market size, and the competitive picture are not proven yet.

The line I would tape to the wall is the one-sentence thesis it hands you: a workflow-specific wedge in a real market, but incumbents already serve this buyer, so the moat is supply, not software. Read that twice. If your defensibility is “supply” (here, access to scarce ex-FDA reviewers), then your real job is not building an app, it is recruiting. That single sentence should reshape the entire plan.

From here the report answers five questions in order. Each one is a gate. If an early gate fails, no amount of polish on the later ones will save the idea.

Gate 1: Is the problem real?

Every idea lives or dies here first. If the pain is not real, severe, and expensive enough that people will pay to make it stop, nothing downstream matters. This gate settles it across two sections: whether the problem is documented, and whether anyone is actively looking for a fix.

Problem Validation: is this a real, expensive pain, or one only I feel?

This is the section that goes hunting for proof the problem exists outside your own head. It gathers real evidence from forums, industry data, and regulatory sources, tags each piece as supporting or undercutting your case, links back to the source, then names the gaps in the evidence. The question it settles is the one founders most love to skip: not “do I believe this is a problem,” but “can I point to strangers who clearly have it and already pay to make it go away?” Getting this wrong is the classic startup death, a year spent building a painkiller for a headache nobody has. That mistake costs you the year. This section costs you a fraction of $49.

THE OPERATOR'S READ

Look at how each piece of evidence is tagged positive or negative and linked to a real source. A tool built to flatter you would only show the green. This one shows a founder burning $800K on a clinical hold and also shows you where the evidence cuts the other way.

The Gaps line is worth the price on its own. It flags that there is no first-person founder quote naming the pain in their own words. Translation: the institutional evidence is strong, but you have not heard a single real buyer say it out loud yet, and it is pointing you at the exact proof to go collect. The blunt bottom line drives it home: documented pain does not mean founders will buy YOUR product, so go talk to fifteen of them before you spend.

Demand Signals: is anyone out there looking for this right now?

A documented problem and live demand are two different things, and this section measures the second one. It checks the places real pull shows up, search intent, community chatter, marketplaces, hiring, and competitor reviews, and rates how strong each signal is. The question is about timing and pull: “are people already spending money on workarounds, or would I have to manufacture the demand from scratch?” Manufacturing demand is the single most expensive thing a young company can attempt. Knowing whether you will have to, before you commit, is worth many multiples of the report’s price.

THE OPERATOR'S READ

Some signals come back strong (community chatter rising, marketplaces actively selling into this) and some come back thin or unverified (live search intent), and it labels each honestly instead of padding the number.

Amber demand is not a no, it is a “verify before you spend,” and it names the exact channels to go check. That is a to-do list, not a verdict, and it is the difference between spending your first marketing dollars on evidence versus on hope.

Gate 2: Is the market worth it?

A real problem in a market that is too small, too crowded, or badly timed is still a bad business. This gate sizes the prize and checks the timing across three sections.

Market Sizing: is the prize big enough to be worth it?

This section sizes the opportunity three ways, top-down (TAM), addressable (SAM), and what you could realistically capture (SOM), then runs a bottom-up sanity check and holds your own estimate up against the math. The question it answers is blunt: “if this works, is it a business worth building, and is it the size of business I actually want?” A $30M niche and a $2B category demand completely different lives, teams, and funding paths. Picking the wrong ambition for the real market is how founders end up raising money they can never return.

THE OPERATOR'S READ

TAM is the vanity number. SOM is the one that decides your life. The report does not just assert a figure, it shows the bottom-up arithmetic: roughly 1,500 new INDs a year, some share buying outside help, at a given spend. That is how an analyst sizes a wedge, and you can pressure-test it line by line.

The sentence that matters: this is a niche, not a category. A $30M-ARR outcome is realistic; a $500M one would need expanding well beyond IND-only or beyond pre-seed. If you are bootstrapping, that is great news. If you are about to pitch a fund a rocket ship, that same sentence tells you your story does not fit the wrapper, and it is far better to learn that before the meeting than during it.

Revenue Ceiling: what is the most this could realistically make?

This is the section that turns a market size into a number you can plan against. It estimates a realistic 24-month revenue ceiling and, crucially, shows the arithmetic behind it: reachable accounts, times capture rate, times average revenue. The question: “if everything goes right, where does the ceiling sit, and does it clear the bar I need it to?” Plenty of ideas are real but quietly capped below the founder’s ambition, and this is where you find that out cheaply, instead of eighteen months in.

THE OPERATOR'S READ

The derivation is what separates this from a horoscope. Roughly 60 active accounts at about $3,600 a month is a real, checkable run rate, not a dream, and you can argue with each input.

It also names what caps growth: the supply of ex-FDA reviewers. If that honest ceiling sits below the numbers your fundraising deck implies, you have two choices, expand the wedge or do not raise on this alone. Either way you are deciding with your eyes open.

Funding and Traction: is smart money already moving on this?

This section checks whether investors are circling the space, which recent rounds have closed in adjacent categories, and whether there is venture money on your exact wedge. The question cuts both ways: “if money is flowing in, the thesis has outside believers; if it is not, is that untapped opportunity, or a signal that people who look at this for a living have already passed?” Either way, you would rather know which story you are walking into before an investor asks.

THE OPERATOR'S READ

Adjacent categories have raised, but there is no recent venture activity on this exact wedge, and it marks its confidence Low and says so out loud. I like that it refuses to spin the ambiguity. Two honest readings sit side by side, either nobody has funded it because it is untapped, or because investors looked and passed, and it hands you both to go resolve rather than picking the flattering one for you.

Gate 3: Can we win?

Say the problem is real and the market is worth it. Can you actually win, or will you get crushed by someone already here? This gate maps the competition, finds the opening, and checks the graveyard, across three sections.

Competitive Landscape: who is already here, and where are they weak?

This section is a teardown, not a logo wall. It profiles the real players and, for each, names a specific gap, the place they leave the door open. The question it answers is the one that decides whether you have a business: “is there a real opening here, or am I about to fight incumbents on their home turf with no edge?” The gaps it surfaces are your wedge candidates, and if it cannot find one, that is the cheapest bad news you will ever get.

THE OPERATOR'S READ

Every competitor comes with a Gap line, and those gaps are your wedge candidates. Here the openings are clear: the big marketplace is generalist with no ex-FDA curation, and the full-service firm sells to later-stage biotech that pre-seed founders cannot afford.

The read to sit with: those two gaps ARE the whole opportunity. Which also means the day an incumbent closes them, your reason to exist gets thin. So the plan has to include getting entrenched before they notice, not just launching and hoping.

White Space and Positioning: is there a lane I can actually own?

This section sorts the market into contested, emerging, and clear territory, then hands you a recommended lane with a positioning sentence you can lift straight onto a landing page. The question: “where exactly do I plant my flag so I am not just a worse version of someone bigger?” It also tells you how defensible that lane really is, and roughly how long your window stays open before a big player notices.

THE OPERATOR'S READ

The clear lane comes with ready-made positioning copy, pre-written from the evidence, which is genuinely useful.

But note the honesty right under it: the lane is real yet narrow, incumbents can copy the positioning, and only the supply of ex-FDA reviewers is truly defensible. It even estimates you may have 12 to 18 months before a big player launches a pre-seed tier. That is your land-grab clock, quantified, so build the plan around it.

Failure Post-Mortems: who has tried this before, and what killed them?

This section digs up prior attempts at similar ideas and, most usefully, names what actually killed each one. The question it answers is the one that saves you from repeating history: “what is the specific way this kind of idea tends to die, and am I exposed to it?” Learning from other people’s graveyards is the cheapest research and development there is.

THE OPERATOR'S READ

Both dead comps here died of the same thing, marketplace cold-start and a race to the bottom on price, where a platform could not attract high-end experts because buyers wanted cheap. That is not trivia. It is precisely this idea’s exposure, because it is also a two-sided marketplace with a scarce, expensive supply side. When the report shows you two bodies that died of the disease you are most likely to catch, design against it from day one.

Gate 4: Can we make money?

A defensible idea with no way to make money is a research project, not a company. This gate pressure-tests the money across three sections: what you can charge, whether the per-customer math works, and the revenue shape that fits.

Pricing and Willingness to Pay: what will people actually pay, and why?

This section recommends a price and, more importantly, anchors it to something real, what your buyer already pays for the alternative, backed by a table of comparable rates. The question: “can I charge enough to build a business, and what is the number people will not blink at?” Most founders pick a price by staring at their own costs or a competitor’s pricing page. This starts from the buyer’s pain and the cost of their status quo, which is where pricing power actually comes from.

THE OPERATOR'S READ

The price is anchored to the buyer’s alternative, an $800K clinical hold and consultants at thousands a month, so a recommended entry point around $2,500 a month reads as a bargain. The comparables table means the number is not plucked from air. Price against the pain, always.

THE OPERATOR'S READ

You also get a full pricing ladder (an entry tier, an expansion tier, an enterprise floor) plus a clear “no free tier” call with a reason: you cannot give regulatory advice away without diluting quality and taking on liability.

And here is the non-obvious insight most founders would miss, spelled out for you: the pricing risk is not on the buyer side, it is on the supply side. Buyers will happily pay given the alternative. The danger is that ex-FDA reviewers will not work for a blended $150 an hour when they can get $600 direct. Your model has to keep the experts happy, not just the customers, and that is the kind of thing you normally only learn after it breaks.

Unit Economics: does the math actually work per customer?

This section runs the four numbers that decide whether growth makes you money or just makes you busy: lifetime value, customer acquisition cost, payback period, and gross margin, each benchmarked, with the assumptions stated. The question: “when I acquire a customer, do I come out ahead, and how long until I do?” It also does the thing most founders will not, it names the single assumption the whole model rests on and the exact point where that assumption turns fatal.

THE OPERATOR'S READ

LTV to CAC, payback, and gross margin are all pre-computed with sources, and it flags that this is a marketplace take-rate margin of 25 to 35 percent, not fat SaaS margin, so you set expectations right. These are the exact four numbers an investor asks for first, and walking in with them already grounded makes you look like you have done the work, because you have.

THE OPERATOR'S READ

Every business model has one load-bearing assumption. Here it is churn: if monthly churn hits 15 percent or higher (customers leaving the moment their IND ships), lifetime value collapses and payback blows past a year. The whole model depends on holding customers past that one event, or expanding them into a second workflow.

A report that names your single most dangerous assumption, and the exact threshold where it turns fatal, has earned its fee right there. Now you know the one metric to watch like a hawk.

Revenue Model: what shape should the business actually take?

This section picks the revenue shape, subscription, usage-based, marketplace take-rate, or a hybrid, and explains why that shape fits this specific idea, not just what number to charge. The question: “how should money actually flow through this business so it is durable and not a constant fight?” The wrong model can quietly cap a good idea, and this is where you choose deliberately instead of defaulting to whatever is easiest to bill.

THE OPERATOR'S READ

It recommends a monthly retainer over one-off project fees, and reasons the choice: a retainer matches the IND-prep cadence, captures predictable recurring revenue, and defends against the expert going direct because the platform owns the relationship. The shape is the strategy here, and it argues the pick rather than asserting it.

Gate 5: So, build it or not?

Everything so far builds to one decision. This gate turns the analysis into a call and a plan, across two sections: what could still go wrong, and the cheapest next moves to find out.

Idea-Level Risks: what is most likely to kill this, and can I see it coming?

This section ranks the real risks by severity and pairs each with a mitigation and, the part that makes it useful, an early-warning sign. The question: “what are the specific ways this fails, and what is the tripwire that tells me it is happening while I can still react?” A risk you cannot detect is just background anxiety. A risk with a named early signal is something you can manage.

THE OPERATOR'S READ

The third column, the early-warning sign, is what turns a worry list into an operating dashboard. “Fewer than 10 signed expert LOIs by month 2” is a tripwire: hit it and you pivot before you have burned the round, not after. That column is the difference between a risk you fret about and one you actually manage.

Recommended Next Steps: what should I do first, and in what order?

This section lays out a short, sequenced set of experiments, in order, each cheap, with a gate at the end. The question it answers is the one that separates thinking from doing: “given all this, what is the smallest set of things I should test before I commit real money?” It is a decision tree, not a to-do list, run these, and if they clear their thresholds, build; if they do not, you have saved yourself a year for the price of a few weeks.

THE OPERATOR'S READ

Five moves, in order, each cheap, and a pass/fail gate at the end. It tells you the cheapest experiments to run before committing capital, sequenced so each one earns the right to the next. Do the four things, let the results decide, and you have de-risked the whole bet for a rounding error.

Can you trust an AI's numbers? (the honesty layer)

It is fair to be skeptical of any tool that hands you a confident number, and you should be. So this is the section I would point a skeptic to first. Every report ends with its Truth Standards: an overall confidence level, an explicit list of what it could not verify and how to check it yourself, and a full list of every source it read. You will also have noticed a “Brutal Truth” line and a confidence tag on each section throughout the report, that is the same principle applied everywhere, state the uncomfortable version plainly and label how sure it is.

THE OPERATOR'S READ

Three things carry the trust argument. An overall confidence level, so you know how much weight to put on the verdict. An explicit Unknowns list that says, for example, “could not pull live Google Trends this session,” then tells you how to check it yourself. And a full list of the sources it actually read.

A tool that tells you what it does not know is worth ten that pretends to know everything. That admission is the opposite of an AI making things up. It means you can audit any claim in the report back to its source, and you know precisely which stones are still unturned. That is the line between a research report and a Magic 8-Ball.

It's validated. Now what? (the go-to-market kit)

Most validation stops at “your idea might work, good luck.” A DeepValidate report keeps going and hands you the execution layer, tuned to your exact idea, so the day you finish reading you have something to do, not just something to think about.

THE OPERATOR'S READ

Fifteen post templates, ready to copy, each pointed at the exact communities where this idea’s buyers actually spend time. This is the boring, high-leverage stuff most founders freeze on, already written for you.

THE OPERATOR'S READ

It sequences the effort over 90 days and, the part I care about most, names the signals that mean it is working: concrete thresholds like at least 15 substantive replies within 7 days, or unprompted DMs from real founders. Analysis tells you if the idea could work. This tells you what result on the ground means it is working.

Proof it is not a rubber stamp

One more thing, because it matters for trusting the whole exercise. Our sample scored 62 and got a cautious yellow light. DeepValidate does not hand everyone a good grade, and if it did, it would be worthless.

THE OPERATOR'S READ

Here is one that came back 38, “High Risk” (three different businesses stitched together with no clear way to make money), and one at 54, “Needs Refinement” (a sharp insight, but the monetization and data costs do not hold up). Different ideas, honestly different verdicts.

A low score is the cheapest thing that can happen to you. It costs one report instead of a year of your life. Being told “not yet, and here is exactly why” is the entire point of running this before you build, not after.

Is a $49 report worth it?

Short answer: the math is lopsided in your favour, and here is why. For $49 you are getting a piece of desk research that would take you a week to assemble yourself, and that a market-research freelancer or a consultant would charge hundreds to low-thousands to produce, usually without the sourced evidence, the unit economics, or the go-to-market kit attached.

But the real comparison is not $49 versus a consultant. It is $49 versus the cost of being wrong. The most common way startups die is not running out of money, it is spending a year and your savings building something nobody wanted badly enough to pay for. Set against that, the price of finding out early rounds to nothing.

That is the whole case. Your downside is $49 and twenty minutes. Your upside is one of two things, a green light you can chase with real conviction, or an honest “not yet, and here is exactly what to fix,” which quietly saves you the most expensive year of your life. Bets that are lopsided do not come along often.

Frequently asked questions

What is a DeepValidate report?

A DeepValidate report is a structured research document that pressure-tests a single startup idea across the dimensions that decide whether it is worth building: the problem, the market, the competition, pricing and unit economics, and the risks. Every finding is backed by a real, linked source and carries a confidence level. It is produced by NELL AI Labs and delivered as a full report you can read, share, and act on.

What's included in a DeepValidate report?

Each report includes an overall score and verdict, a problem-validation section with sourced evidence, demand signals, market sizing (TAM, SAM, and a bottom-up SOM), a realistic revenue ceiling, a competitive teardown, a positioning and white-space map, failure post-mortems of similar ideas, pricing and willingness-to-pay guidance, unit economics, a recommended revenue model, ranked risks with mitigations and early-warning signs, sequenced next steps, a full sources-and-confidence section, and a ready-to-use go-to-market kit with community templates and a 90-day plan.

How much does a DeepValidate report cost?

A DeepValidate report costs $49. You can create a free account to see how it works, then run a full report on the idea you want validated for $49.

How is DeepValidate different from other AI idea-validation tools?

Most free AI validators return a confident-sounding paragraph and a score with nothing behind it. A DeepValidate report is built the opposite way: every claim is tied to a real, linked source, each section carries a confidence level, and it openly lists what it could not verify. It also does not stop at a verdict, you get the competitive teardown, the pricing and revenue model, the risks, and a go-to-market kit built for your specific idea.

How accurate is DeepValidate, and can I trust an AI's analysis?

DeepValidate does not try to predict the future, and you should be wary of any tool that claims to. What it does is ground every finding in public evidence you can check yourself, flag its confidence on each dimension, and list what it could not verify so you know exactly where a human still needs to look. Treat it as the most thorough first-pass research an analyst could do in an afternoon, with its sources shown, rather than a guarantee.

Who is DeepValidate for?

DeepValidate is built for early-stage and aspiring founders deciding whether an idea is worth their time, especially people about to apply to an accelerator, build in public, or quit a job to go all-in. It is equally useful for anyone sitting on several ideas who wants an evidence-based way to decide which one to pursue first.

What happens after I get my report?

Your report ends with a sequenced set of next steps, the cheapest experiments to run before committing real money. From there, founders who get a promising result typically move into deeper build-and-go-to-market work, and NELL’s Launchpad and Builder programs pick up where the report leaves off for ideas that clear the bar. If the verdict is “not yet,” the report tells you exactly what to fix before trying again.

Does a low score mean I should give up on my idea?

Not necessarily. A low score means the idea, as currently framed, has a specific weakness the report will name, often a market that is too small, a crowded field with no clear wedge, or shaky unit economics. Sometimes that is fatal; often it is a prompt to reframe the idea, narrow the wedge, or fix the model and re-validate. The point of the score is to tell you what to work on, not just whether to proceed.

The bottom line

A DeepValidate report gives you four things that are hard to get anywhere else in an afternoon. An honest read on whether the problem, the market, the competition, and the money add up. The evidence and sources behind every call, including how confident it is and what it could not verify. A sequenced set of experiments to run before you spend real money. And a go-to-market kit built for your exact idea.

It will not build the company for you, and it is not a guarantee, it is desk research, which makes it the strongest starting position you can buy for $49, not proof. Real proof shows up when actual buyers put their name or their money on the line, and the report points you straight at that next step. Treat it as the map. You still have to walk the ground.

Every DeepValidate report includes the competitive landscape, the market sizing, a pricing and revenue model, and the idea-level risks, each backed by sourced evidence and a confidence level. What it says about your idea, you find out by running yours.

Validate your idea for $49 at nellailabs.ai